BEVERLY HILLS, Calif.,
March 24, 2015 /PRNewswire/ -- Rich
Pharmaceuticals, Inc. (OTCQB: RCHA) ("Rich Pharmaceuticals" or
the "Company"), a clinical-stage biotechnology company focused on
developing innovative therapies in oncology, with initial
concentration in treating Acute Myelocytic Leukemia (AML) and
Hodgkin's Lymphoma, announced that it has entered into a Letter of
Intent with The Faculty of Medicine at Khon Kaen University,
Thailand to conduct clinical
trials using Rich's lead molecule, RP-323 in treating AML patients.
The Faculty of Medicine at Khon Kaen University has established
itself as a center for world-class research. Presently, the
Faculty has four Research Centers of Excellence and 23 Research
Groups doing clinical research across numerous disease states with
emphasis in conducting oncology clinical trials. For more
information on the Faculty of Medicine, Khon Kaen University see:
http://www.md.kku.ac.th/en/. The commencement of the clinical
studies is conditioned upon establishing a budget and timeline for
the studies, and the execution of a definitive Clinical Study
Agreement with the Faculty of Medicine at Khon Kaen
University. The clinical studies are estimated to include 36
patients and 3 separate sites.
"As we move closer to beginning our AML clinical program, we are
continuing to work diligently in securing additional principal
investigators in the United States
and finalizing our IND submission to the FDA," said Ben Chang, CEO of Rich Pharmaceuticals.
Rich Pharmaceuticals' RP-323 is a phorbol ester, which induces
differentiation and/or apoptosis in multiple cell lines and primary
cells, activates protein kinase C (PKC), and modulates the activity
of multiple downstream cell signaling pathways, including
mitogen-activated protein kinase (MAPK) pathways. TPA induces
PKC to produce NF kappa, which produces NF kappa B that has the
ability to regulate cellular responses by entering into the nucleus
of cell. NF kappa B binds to DNA and changes the nature of the cell
and (1) induces differentiation; (2) induces proliferation; (3)
cytokine induction; (4) and/or apoptosis.
Acute myelocytic leukemia (AML), also known as acute
myelogenous leukemia, is the most common acute leukemia type that
affects adults. AML is an aggressive form of cancer of the
blood and the bone marrow, characterized by the rapid growth of
abnormal white blood cells that accumulate in the bone marrow and
interfere with the production of normal white blood cells. In
the U.S., about 18,000 new cases of AML are diagnosed annually.
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (OTCQB: RCHA) is a biopharmaceutical
company developing a treatment for
Acute Myelocytic Leukemia (AML)/white blood cell
elevation, Hodgkin's Lymphoma and other blood related
diseases. Rich Pharmaceuticals' goal is to extend refractory
patients life expectancy and increase quality of life. Rich
Pharmaceuticals' primary development stage product candidate,
RP-323, is being designed to treat
blood and cancer related diseases through non-evasive outpatient
facilities. Find out more at www.richpharmaceuticals.com.
For more infomraiton about AML see for example:
http://www.cancer.gov/cancertopics/pdq/treatment/adultAML/Patient/page1
http://www.cancer.org/cancer/leukemia-acutemyeloidaml/
For more information about Hodgkin's Lymphoma see for
example:
http://www.cancer.gov/cancertopics/types/hodgkin
http://www.cancer.org/cancer/hodgkindisease/
Notice Regarding Forward-Looking Statements:
This news release contains "forward-looking statements" as that
term is defined in Section 27(a) of the Securities Act of 1933, as
amended, and Section 21(e) of the Securities Exchange Act of 1934,
as amended. Statements in this press release that are not purely
historical are forward-looking statements and include any
statements regarding beliefs, plans, expectations or intentions
regarding the future. Such forward-looking statements include,
among other things, references to novel technologies and methods,
our business and product development plans, our financial
projections or market information. Actual results could differ from
those projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or
technologies and operating as a development stage company; our
ability to raise the additional funding we need to continue to
pursue our business and product development plans and to conduct
our planned clinical studies; our ability to develop and
commercialize products based on our technology platform;
competition in the industry in which we operate; and general market
conditions. These forward-looking statements are made as of the
date of this news release, and we assume no obligation to update
the forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans,
expectations and intentions contained in this press release are
reasonable, there can be no assurance that any such beliefs, plans,
expectations or intentions will prove to be accurate. Investors
should consult all of the information set forth herein and should
also refer to the risk factors disclosure outlined in the reports
and other documents we file with the SEC, available at
www.sec.gov.
Contact:
Ben Chang, CEO
9595 Wilshire Blvd., Suite 900
Beverly Hills, CA 90212
424-230-7001 EXT 105
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rich-pharmaceuticals-inc-announces-letter-of-intent-with-faculty-of-medicine-at-khon-kaen-university-to-conduct-acute-myelocytic-leukemia-clinical-trials-300055020.html
SOURCE Rich Pharmaceuticals, Inc.